New research explains how an enzyme acts as a kind of thermostat that responds to and adjusts levels of cholesterol in the cell. This insight could lead to new strategies for combating high cholesterol.
Heart disease and fatty clogs in the arteries go hand in hand. But new evidence suggests the fatty molecules might come not only from what you eat, but from the bacteria in your mouth, scientists report. The research may explain why gum disease is associated with heart trouble.
We can add one more thing to the list of traits affected by genetics: how our bodies respond to a particular diet. Research in animal models with different genetics shows that one diet really doesn't fit all, and what works for some may not be best for others, according to a new study.
Tofu sausages on the barbecue, followed by cake made with bananas instead of eggs? There is no doubt that the vegan diet is in vogue. Alongside the proven positive effects on health, however, there are also risks.
Medical researchers have illuminated a critical player in cholesterol metabolism that acts as a molecular guardian in cells to help maintain cholesterol levels within a safe, narrow range. Known as Nrf1, it both senses and responds to excess cholesterol, and could represent a potential new therapeutic target in a multitude of diseases where cholesterol metabolism is disrupted.
LDL-cholesterol-lowering drug evolocumab reduced risk of major cardiovascular events and major adverse limb events among peripheral artery disease sub-population from the FOURIER trial. A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to patients with peripheral artery disease.
After decades of individual attempts to identify the structure of the main building block of HDL (high-density lipoproteins), the so-called 'good' cholesterol that associates with protection from cardiovascular disease, a research team representing eight academic institutions across the US and Australia has come to agreement on a predictive model.
If you have a heart attack or stroke, it's important to get your 'bad' cholesterol measured by your doctor on a follow up visit. Researchers have found that one step is significantly associated with a reduced risk of suffering another serious cardiovascular episode.
In the largest study of its kind, less than half of patients prescribed the new class of cholesterol drugs, PCSK9 inhibitors, received insurance approval even if patients had atherosclerotic cardiovascular disease (plaque build-up of the arteries) or markedly elevated bad cholesterol. The most significant factor associated with approval was insurance type, with Medicare patients more likely to be approved than those with private insurance.
A breakthrough discovery could change the way we treat cholesterol. Researchers found new evidence that challenges a 40-year notion of how fast we eliminate it from our bodies. This accidental discovery reveals a new pathway in the cholesterol-elimination chain that will be key to developing new drugs to lower cholesterol.
Heart disease patients who practice yoga in addition to aerobic exercise saw twice the reduction in blood pressure, body mass index and cholesterol levels when compared to patients who practiced either Indian yoga or aerobic exercise alone, according to new research.
High cholesterol levels have been associated with breast cancer spreading to other sites in the body, but doctors and researchers don't know the cause for the link. A new study found that the culprit is a byproduct of cholesterol metabolism that acts on specific immune cells so that they facilitate the cancer's spread instead of stopping it.